A Phase I study of safety and pharmacokinetics of fruquintinib, a novel selective inhibitor of vascular endothelial growth factor receptor-1, -2, and -3 tyrosine kinases in Chinese patients with advanced solid tumors

Discovery of fruquintinib, a potent and highly selective small molecule inhibitor of VEGFR 1, 2, 3 tyrosine kinases for cancer therapy

(2014) Qiaoling Sun et al.   CANCER BIOLOGY & THERAPY

Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics

(2014) Yi Gu et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Regorafenib in metastatic colorectal cancer

(2014) Andrea Sartore-Bianchi et al.   Expert Review of Anticancer Therapy

Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

(2013) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase I Dose-Escalation Study of Regorafenib (BAY 73-4506), an Inhibitor of Oncogenic, Angiogenic, and Stromal Kinases, in Patients with Advanced Solid Tumors

(2012) K. Mross et al.   CLINICAL CANCER RESEARCH

Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma

(2012) Dmitry A. Nosov et al.   JOURNAL OF CLINICAL ONCOLOGY

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Concise Drug Review: Pazopanib and Axitinib

(2012) R. M. J. M. van Geel et al.   ONCOLOGIST

Toxicities of Targeted Therapy and Their Management in Kidney Cancer

(2011) Giuseppe Di Lorenzo et al.   EUROPEAN UROLOGY

Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial

(2011) Brian I Rini et al.   LANCET

It takes two to tango: Combinations of conventional cytotoxics with compounds targeting the vascular endothelial growth factor–vascular endothelial growth factor receptor pathway in patients with solid malignancies

(2009) Ingrid A. Boere et al.   CANCER SCIENCE

Sorafenib

(2009) Gillian M. Keating et al.   DRUGS

Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma

(2009) Robert J. Motzer et al.   JOURNAL OF CLINICAL ONCOLOGY

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

(2008) M. E. Lacouture et al.   ANNALS OF ONCOLOGY